A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2844-2849

  Ajani, J A ^a   Xiao, L ^a   Roth, J A ^a   Hofstetter, W L ^a   Walsh, G ^a   Komaki, R ^a   Liao, Z ^a   Rice, D C ^a   Vaporciyan, A A ^a   Maru, D M ^a   Lee, J H ^a   Bhutani, M S ^a   Eid, A ^a   Yao, J C ^a   Phan, A P ^a   Halpin, A ^a   Suzuki, A ^a   Taketa, T ^a   Thall, P F ^a   Swisher, S G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoradiation; Esophageal carcinoma; Esophageal preservation; Induction chemotherapy; Pathologic complete response; Randomized trial

Indexed keywords

FLUOROURACIL; OXALIPLATIN;

ADULT; AGE; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; BAYES THEOREM; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CARDIOVASCULAR DISEASE; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG SAFETY; ESOPHAGUS CANCER; FATIGUE; FEMALE; FISHER EXACT TEST; FOLLOW UP; GENDER; HISTOLOGY; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL;

CHEMORADIATION; ESOPHAGEAL CARCINOMA; ESOPHAGEAL PRESERVATION; INDUCTION CHEMOTHERAPY; PATHOLOGIC COMPLETE RESPONSE; RANDOMIZED TRIAL;

ADULT; AGED; BAYES THEOREM; CHEMORADIOTHERAPY; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PREOPERATIVE PERIOD; REMISSION INDUCTION;

EID: 84887093494     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt339     Document Type: Article

References (23)

1. Van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084.
2. Ajani JA, Barthel JS, Bentrem DJ et al. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw 2011; 9: 830-887.
3. Rizk NP, Venkatraman E, Bains MS et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 2007; 25: 507-512.
4. Berger AC, Farma J, Scott WJ et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-4337.
5. Rohatgi P, Swisher SG, Correa AM et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 2005; 104: 2365-2372.
6. Chirieac LR, Swisher SG, Ajani JA et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005; 103: 1347-1355.
7. Kelsen DP, Ginsberg R, Pajak TF et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-1984.
8. Allum WH, Stenning SP, Bancewicz J et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27: 5062-5067.
9. Stahl M, Walz MK, Stuschke M et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-856.
10. Ajani JA, Komaki R, Putnam JB et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 2001; 92: 279-286.
11. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103-115.
12. Gelman A, Carlin JB, Stern HS et al. Bayesian Data Analysis. New York: Chapman and Hall 2004.
13. Fisher R. On the interpretation of x2 from contingency tables, and the calculation of P. J R Stat Soc 1922; 85: 85-87.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Stat Assoc 1958; 53: 457-481.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1996; 60: 163-170.
16. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187-220.
17. Wu TT, Chirieac LR, Abraham SC et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol 2007; 31: 58-64.
18. Kim JY, Correa AM, Vaporciyan AA et al. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg 2012; 93: 207-212.
19. Ajani JA, Correa AM, Hofstetter WL et al. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 2012; 23: 2638-2642.
20. Ajani JA, Wang X, Hayashi Y et al. Validated biomarker signature that predicts pathologic response to preoperative chemoradiation therapy with high specificity and desirable sensitivity levels in patients with esophageal cancer. J Clin Oncol 2011; 29: Suppl., Abstract 4027 http://meetinglibrary.asco.org/content/77734-102.
21. Vogelstein B, Papadopoulos N, Velculescu VE et al. Cancer genome landscapes. Science 2013; 339: 1546-1558.
22. Haddad R, O'Neill A, Rabinowits G et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013; 14: 257-264.
23. Miyata H, Yamasaki M, Kurokawa Y et al. Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs. J Surg Oncol 2012; 106: 441-447.